Cover Image

Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance

Background: Evolocumab is a humanized immunoglobulin G2 monoclonal antibody, directed against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), prescribed in hypercholesterolemic patients. The safety profile of this drug is currently defined by the data of pre-authorization clinical trials. The...

Full description

Saved in:

Bibliographic Details
Main Authors:	Fabrizio Calapai (Author), Carmen Mannucci (Author), Mariaconcetta Currò (Author), Luigi Cardia (Author), Emanuela Esposito (Author), Gioacchino Calapai (Author), Ilaria Ammendolia (Author)
Format:	Book
Published:	MDPI AG, 2024-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Suspected oncologic adverse reactions associated with interleukin‐23 inhibitors in EudraVigilance: Comparative study and gender distribution
by: Fabrizio Calapai, et al.
Published: (2023)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
by: Fabrizio Calapai, et al.
Published: (2023)

Response to "Evaluating Adverse Events in Databases"
by: Fabrizio Calapai, et al.
Published: (2023)

Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2)
by: Ilaria Ammendolia, et al.
Published: (2024)

Pharmacovigilance on cannabidiol as an antiepileptic agent
by: Ilaria Ammendolia, et al.
Published: (2023)

Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007-2018
by: Iwona Popiołek, et al.
Published: (2019)

Post-Marketing Surveillance of Statins-A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance
by: Gabriela Pop, et al.
Published: (2022)

Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database
by: Atul Khurana, et al.
Published: (2024)

Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
by: Giuseppe Cicala, et al.
Published: (2024)

Seriousness and outcomes of reported adverse drug reactions in old and new antiseizure medications: a pharmacovigilance study using EudraVigilance database
by: Michael Magdy Fahmy Girgis, et al.
Published: (2024)

Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives
by: Marco Sardella, et al.
Published: (2019)

Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database
by: Liberata Sportiello, et al.
Published: (2023)

Drug-Drug Interactions of Selective Serotonin Reuptake Inhibitors: A Pharmacovigilance Study on Real-World Evidence from the EudraVigilance Database
by: Carmen Maximiliana Dobrea, et al.
Published: (2024)

Cannabinoids, Blood-Brain Barrier, and Brain Disposition
by: Fabrizio Calapai, et al.
Published: (2020)

A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database
by: Claudiu Morgovan, et al.
Published: (2023)

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
by: Michele Gringeri, et al.
Published: (2021)

Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database
by: Cristina Scavone, et al.
Published: (2022)

Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)
by: Stefania Chiappini, et al.
Published: (2022)

Characteristics and completeness of spontaneous reports by reporter's role in Germany: An analysis of the EudraVigilance database using the example of opioid‐associated abuse, dependence, or withdrawal
by: Kathrin Jobski, et al.
Published: (2023)

Effects of Physical Exercise and Motor Activity on Oxidative Stress and Inflammation in Post-Mastectomy Pain Syndrome
by: Marco Calapai, et al.
Published: (2023)

Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review
by: Luigi Cardia, et al.
Published: (2018)

Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase
by: Fabrizio Calapai, et al.
Published: (2023)

A Pharmacovigilance Study Regarding the Risk of Antibiotic-Associated <i>Clostridioides difficile</i> Infection Based on Reports from the EudraVigilance Database: Analysis of Some of the Most Used Antibiotics in Intensive Care Units
by: Bogdan Ioan Vintila, et al.
Published: (2023)

Nutraceuticals against Oxidative Stress in Autoimmune Disorders
by: Carmen Mannucci, et al.
Published: (2021)

Periocular Erythema and Eczema after Local Application of Calendula Officinalis in Pediatric Age
by: Vincenzo Patella, et al.
Published: (2017)

Efficacy and safety of the syrup "KalobaTUSS®" as a treatment for cough in children: a randomized, double blind, placebo-controlled clinical trial
by: Ilaria Carnevali, et al.
Published: (2021)

Citrus bergamia essential oil: from basic research to clinical application
by: Michele eNavarra, et al.
Published: (2015)

Correlation of s-IgA and IL-6 Salivary with Caries Disease and Oral Hygiene Parameters in Children
by: Giuseppe Lo Giudice, et al.
Published: (2019)

Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia
by: Abdulaali R. Almutairi, et al.
Published: (2024)

Long-Term Effects of High Doses of Nicotine on Feeding Behavior and Brain Nitric Oxide Synthase Activity in Female Mice
by: Carmen Mannucci, et al.
Published: (2005)

Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
by: Cicero AF, et al.
Published: (2015)

Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database
by: Tuhin Maity, et al.
Published: (2021)

Cost-effectiveness of Evolocumab in Cardiovascular Disease: A Systematic Review
by: Nashmil Ghadimi, et al.
Published: (2024)

FDA Has Approved Evolocumab for Theatment of Familial Hypercholesterolemia in Children
by: article Editorial
Published: (2021)

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
by: Syed Raza Shah, et al.
Published: (2017)

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
by: Dixon DL, et al.
Published: (2017)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
by: Huang CC, et al.
Published: (2019)

Correlation between Oral Hygiene and IL-6 in Children
by: Roberto Lo Giudice, et al.
Published: (2020)

A Randomized, Double-Blinded, Clinical Trial on Effects of a Vitis vinifera Extract on Cognitive Function in Healthy Older Adults
by: Gioacchino Calapai, et al.
Published: (2017)